• image description

    Research that Makes a Difference in the Lives of Cancer Patients

    Genprex is focused on providing new solutions to solve
    today’s problems in fighting cancer.

    Learn More
  • image description

    Striving to Provide a Healthier Tomorrow for Cancer Patients

    Genprex is dedicated to improving patients’ lives by increasing the treatment potential of currently marketed and developmental cancer drugs.

    Learn More
  • image description

    Focused on Building Strong, Long-term Relationships

    Genprex is forming commercial partnerships for worldwide development and marketing of our products and technology applications.

    Learn More

Genprex is a privately held, clinical-stage biopharmaceutical company developing nanovesicle therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. The company’s pan-kinase inhibitors work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways. These biologic therapies target key oncogenic pathways to treat tumors and cancer metastases at the molecular level without harming normal cells. Used in combination with other targeted therapies, these drugs overcome genomic limitations inherent with targeted therapies including tyrosine kinase inhibitory drugs (TKIs). Genprex technologies also can be used to reduce drug resistance in patients with intrinsic or acquired drug resistance. Our products will broadly participate in the global oncology marketplace by addressing the unmet medical needs of cancer patients and expanding populations of patients benefiting from our combination treatments.

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Read More...

3p21.3 Tumor Suppressors, TUSC2/FUS1 Mechanisms of Action and Synergies in Drug Combination Applications

Read More

We are committed to discovering, developing and commercializing targeted molecular therapies to benefit patients

Learn More